Showing 1 - 7 results of 7 for search 'Morse Michael A', query time: 0.04s Refine Results
  1. 1
    Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

    Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma by Gillies Stephen D, Kovar Andreas, Gooding William, Whiteside Theresa L, Atkins Michael B, Kirkwood John M, Ribas Antoni, Kashala Oscar, Morse Michael A

    Published 2009-07-01
    Get full text
    Article
  2. 2
    Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines

    Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines by Rangwala Fatima, Williams Kevin P, Smith Ginger R, Thomas Zainab, Allensworth Jennifer L, Lyerly H, Diehl Anna, Morse Michael A, Devi Gayathri R

    Published 2012-09-01
    Get full text
    Article
  3. 3
    Investigation of HIFU-induced anti-tumor immunity in a murine tumor model

    Investigation of HIFU-induced anti-tumor immunity in a murine tumor model by Lyerly H Kim, Morse Michael A, Pua Eric C, Sankin Georgy N, Liu Yunbo, Yang Xiao, Hu Zhenlin, Clay Timothy M, Zhong Pei

    Published 2007-07-01
    Get full text
    Article
  4. 4
    Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2

    Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2 by Anders Carey, Blackwell Kimberly L, Marcom Paul, Niedzwiecki Donna, Osada Takuya, Hobeika Amy, Morse Michael A, Devi Gayathri R, Lyerly H Kim, Clay Timothy M

    Published 2007-09-01
    Get full text
    Article
  5. 5
    First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

    First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer pati... by Berinstein Neil L, Karkada Mohan, Morse Michael A, Nemunaitis John J, Chatta Gurkamal, Kaufman Howard, Odunsi Kunle, Nigam Rita, Sammatur Leeladhar, MacDonald Lisa D, Weir Genevieve M, Stanford Marianne M, Mansour Marc

    Published 2012-08-01
    Get full text
    Article
  6. 6
    Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides

    Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides by Lyerly Herbert K, Clay Timothy M, Morse Michael A, Ghanayem Manar, Comatas Karrie, Summers Amanda, Payne Janice K, Hassler Jeffrey, Maecker Holden T, Bhatia Sonny, Ghanekar Smita A, Maino Vernon C, delaRosa Corazon, Disis Mary L

    Published 2008-03-01
    Get full text
    Article
  7. 7
    Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT

    Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT by Morse Michael A, Clay Timothy M, Summers Amanda, Chang Jennie C, Payne Janice K, Kuus-Reichel Kristine, Ghanekar Smita A, Maino Vernon C, Bhatia Sonny, Moon James, Maecker Holden T, Lyerly H Kim, DeLaRosa Corazon, Ankerst Donna P, Disis Mary L

    Published 2005-07-01
    Get full text
    Article

Search Tools: